After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
KalVista Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of KalVista Pharmaceuticals Inc is $500.49M. A total of 0.69 million shares were traded on the day, compared to an average of 390.98K shares.
In the most recent transaction, Palleiko Benjamin L sold 7,352 shares of KALV for 12.19 per share on Sep 09 ’24. After the transaction, the CHIEF EXECUTIVE OFFICER now owns 250,800 company shares. In a previous transaction on Aug 23 ’24, Audhya Paul K. sold 2,135 shares at 12.40 per share. KALV shares that CHIEF MEDICAL OFFICER owns now total 83,745.
Among the insiders who sold shares, Yea Christopher disposed of 1,916 shares on Aug 23 ’24 at a per-share price of $12.40. This resulted in the CHIEF DEVELOPMENT OFFICER holding 85,676 shares of KALV after the transaction. In another insider transaction, Audhya Paul K. sold 7,973 shares at $12.01 per share on Aug 19 ’24. Company shares held by the CHIEF MEDICAL OFFICER now total 80,880.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, KALV has a high of $16.88 and a low of $7.21.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. KALV’s latest balance sheet shows that the firm has $166.20M in Cash & Short Term Investments as of fiscal 2022. There were $8.19M in debt and $11.58M in liabilities at the time. Its Book Value Per Share was $4.01, while its Total Shareholder’s Equity was $185.09M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KALV is Buy with a score of 4.83.
